secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001193125-24-060001
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences reports FY2023 revenue $113.3M; cash runway into Q4 2025; INHBE candidate selected
--------------------------------------------------------------------------------

- Cash and equivalents $200.4M at Dec 31, 2023; additional $34M received in Q1 2024; runway expected into Q4 2025.
- Full-year revenue $113.3M (2022: $3.6M) driven by GSK and Takeda collaborations; net loss improved to $57.5M from $161.8M.
- INHBE lead clinical candidate for obesity selected; GalNAc-siRNA shows potent silencing, weight loss without muscle loss; trial initiation expected Q1 2025.
- Proof-of-mechanism data for WVE-006 in AATD expected 2024; WVE-N531 dystrophin data in DMD expected Q3 2024; WVE-003 multi-dose HD data expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524060001/0001193125-24-060001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524060001/d761944d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-060001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer